AIT Worldwide Logistics Announces Strategic Partnership With Greenbriar Equity Group
16.2.2026 15:03:00 CET | Business Wire | Press Release
Supply chain solutions leader AIT Worldwide Logistics (“AIT”) has entered into a definitive agreement to partner with Greenbriar Equity Group, L.P. (“Greenbriar”) in support of the global freight forwarder’s next chapter of growth. Financial terms of the private transaction were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260216984391/en/
AIT Worldwide Logistics' strategic partnership with Greenbriar Equity Group represents one of the largest private acquisitions ever in the global freight forwarding sector.
The deal marks the culmination of five successful years with The Jordan Company, L.P. (“TJC”). TJC, alongside key members of AIT’s executive leadership team, will remain invested in the company. Over the course of the company’s relationship with TJC, AIT has dramatically expanded its global footprint, acquired 14 businesses, and increased its gross revenue by more than 300%.
The agreement with Greenbriar, a Greenwich, Connecticut-based specialist investor focused on partnering with and growing market-leading companies, coincides with the initial stages of AIT’s plan to achieve its cultural, financial, and quality goals by 2030. Greenbriar’s investment and TJC’s continuing involvement enable an accelerated growth trajectory for AIT – both organically and via acquisition – as detailed by its long-term strategy.
According to AIT’s Chairman and Chief Executive Officer, Vaughn Moore, the deal represents one of the largest private acquisitions ever in the global freight forwarding sector.
“AIT is entering a new era with Greenbriar as the company continues to strive toward our vision to become the global logistics provider respected for delivering a world-class experience,” Moore said. “With Greenbriar’s support, AIT gains momentum to pursue new expansion in key global markets, including investments in talent and technology, while continuing to deliver customized supply chain solutions that meet and exceed the needs of our customers. We are still a privately held company, maintaining independence, brand identity, and continuity delivered by our proven, experienced leadership team.”
Greenbriar’s $15+ billion in cumulative capital commitments, coupled with more than 25 years of investing in transportation and logistics firms, make it an ideal partner for AIT as the company advances its growth strategy in pursuit of its 2030 objectives.
“AIT has built an exceptional global platform defined by strong leadership, operational excellence, and a deeply embedded service culture,” said Greenbriar Managing Director, Michael Wang. “As global supply chains continue to evolve in complexity, we believe AIT is uniquely positioned to meet increasing demand for integrated logistics solutions across technology, life sciences, and other specialized sectors. Our goal is to support AIT’s long-term growth, while preserving the entrepreneurial spirit and operational discipline that have defined the company’s success. We are excited to partner with Vaughn and the entire leadership team as AIT enters its next phase of expansion.”
The closing of the transaction is expected to be completed before the fourth quarter of 2026, subject to customary closing conditions and other regulatory approvals.
Morgan Stanley & Co. LLC acted as lead financial advisor and Harris Williams LLC also acted as financial advisor to AIT on the transaction. Womble Bond Dickinson LLP provided legal representation for AIT’s executive management team.
Goldman Sachs & Co. LLC and Citizens Capital Markets & Advisory acted as lead financial advisors to Greenbriar.
About AIT Worldwide Logistics
AIT Worldwide Logistics is a global freight forwarder that helps companies grow by expanding access to markets all over the world where they can sell and/or procure their raw materials, components and finished goods. For over 45 years, the Chicago-based supply chain solutions leader has relied on a consultative approach to build a global network and trusted partnerships in nearly every industry, including aerospace, energy, high-tech, home delivery, life sciences, marine and more. Backed by scalable, user-friendly technology, AIT’s flexible business model customizes end-to-end deliveries via sea, air, road and rail — on time and on budget. With expert teammates staffing more than 150 worldwide locations in Asia, Europe, the Middle East and North America, AIT’s full-service options also include customs clearance, warehouse management and white glove services. Learn more at www.aitworldwide.com.
Our Mission
At AIT, we provide solutions to earn our customers' trust, leveraging our products, regions and vertical markets, all backed by a high-performance culture.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260216984391/en/
Contacts
MEDIA CONTACT:
Matt Sanders
Communications Director
+1 (630) 766-8300
msanders@aitworldwide.com
AIT Worldwide Logistics, Inc.
Global Headquarters
Itasca, IL 60143
800-669-4AIT (4248)
www.aitworldwide.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.aitworldwi
de.com%2F&esheet=54425767&newsitemid=20260216984391&lan=en-US&anchor=www.aitworl
dwide.com&index=2&md5=5a37de45272484b337ada887bbd5c85e
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom